Combination therapy of radiation and intratumoral directo injection of dendritic cells for advanced esophageal cancer, a phase I study.

Combination therapy of radiation and intratumoral directo injection of dendritic cells for advanced esophageal cancer, a phase I study. - Chiba RT-DC therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011079

Enrollment

Registered

2013-07-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Direct intratumoral injection of dendtiric cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Squamous cell carcinoma 2.All standard treatments has been failured, and there shuould be at least one leasion to which dentritic cells can be diretly injected. 3.At least one measurable leasion. 4. Age: 20 and more, 74 and younger. 5.Performance Status (ECOG):0 or1 6.At least 4 weeks or more has been past since previous treatments. 7.Two or more months of survival can be expected. 8.Apparopriate organ functions are preserved.

Exclusion criteria

Exclusion criteria: 1.Previous immunotehrapy, previous radiation therapy 2.Fistula 3.Obvious infection 4.Alb 3.0mg/ml or less 5.Uncontrolable pleural effusion, ascites, pericardial effusion 6.Severe heart failure 7.Respiratory or other complications 8.Psychological disorders 9.Active double cancers 10.Steroid usage 11.Hepatitis B or C. HIV, HTLV-1 positive 12.Hypersensitivity for albumin 13.Pregnant woman 14.Autoimmune diseases 16.Patients who cannot undergo apheresis.

Design outcomes

Primary

Measure	Time frame
safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026